# EDGAR Filing Document

**Accession Number:** 0001843724
**File Stem:** 0000000000-25-005998
**Filing Date:** 2025-6
**Character Count:** 6946
**Document Hash:** b2dfa864cc07a434b7698a3cbfb4c013
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-005998.hdr.sgml**: 20250822

**ACCESSION NUMBER**: 0000000000-25-005998

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250606

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LanzaTech Global, Inc.
- **CENTRAL INDEX KEY:** 0001843724
- **STANDARD INDUSTRIAL CLASSIFICATION:** INDUSTRIAL ORGANIC CHEMICALS [2860]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 861763050
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-40282

**BUSINESS ADDRESS:**
- **STREET 1:** 8045 LAMON AVENUE
- **STREET 2:** SUITE 400
- **CITY:** SKOKIE
- **STATE:** IL
- **ZIP:** 60077
- **BUSINESS PHONE:** 847-324-2400

**MAIL ADDRESS:**
- **STREET 1:** 8045 LAMON AVENUE
- **STREET 2:** SUITE 400
- **CITY:** SKOKIE
- **STATE:** IL
- **ZIP:** 60077

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMCI Acquisition Corp. II
- **DATE OF NAME CHANGE:** 20210201
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001539497-25-001532

## Text-Extract

```

                                                            June 6, 2025

Jennifer Holmgren, Ph.D.
Chief Executive Officer and Director
LanzaTech Global, Inc.
8045 Lamon Avenue
Suite 400
Skokie, Illinois 60077

       Re: LanzaTech Global, Inc.
           Preliminary Proxy Statement on Schedule 14A
           Filed May 27, 2025
           File No. 001-40282
Dear Jennifer Holmgren Ph.D.:

       We have reviewed your filing and have the following comments.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Preliminary Proxy Statement on Schedule 14A filed May 27, 2025
What is the effect of the Special proposals on our stockholders?, page 18

1.     We note your disclosure that, if the stockholders approve the proposals
in this proxy
       statement, any Preferred Stock voting cap would fall away and the voting
power of
       the existing holders of Common Stock will decrease. We also note your
disclosure on
       page 10 that the voting rights of the Preferred Stock are capped as
described in the
       Certificate of Designation unless and until the stockholders approve the
Nasdaq
       Listing Rule Proposals. Please revise the "Potential Effects of the
Nasdaq Listing
       Approvals" disclosures on pages 47 and 49 to discuss that the approval
of these
       proposals will result in any Preferred Stock voting cap falling away and
why.
Proposal 4
The Increased Authorized Share Proposal, page 29

2.     We note your disclosure that each Warrant is exercisable at a price
equal to
       $0.0000001 per Warrant Share, but the warrants will not be exercisable
unless and
 June 6, 2025
Page 2

       until, among other things, the Requisite Stockholder Approvals are
obtained and you
       consummate a subsequent financing (the "Conditions to Exercise"). We
also note your
       disclosure that, if the Conditions to Exercise are satisfied, each
warrant will be
       "deemed automatically exercised on a cashless, net-exercise basis."
Therefore, it
       appears that although the Warrant Shares are exercisable for a nominal
amount, the
       Conditions to Exercise will result in the warrants effectively being
exercised only on a
       cashless basis. Please revise to clarify the significance of the
cashless exercise to
       warrant holders, including whether the cashless exercise will have any
impact on the
       amount of shares per warrant received by each holder.
3.     We refer to your disclosure on page 18 that the issuance of the
additional authorized
       shares pursuant to the Special Proposals will dilute the economic and
voting interests
       of your existing stockholders, including upon the conversion of the
preferred stock
       and upon the issuance of the warrant shares. Please revise to add
prominent risk factor
       disclosure addressing risks associated with the significant potential
dilution from the
       exercise of the Warrants, the issuance of the Warrant Shares, and the
issuance of
       shares underlying a Subsequent Financing to your existing stockholders.
The risk
       factor should also disclose the maximum number of shares that may be
issuable upon
       exercise of the warrants and financing as compared to the number of
shares currently
       outstanding. Please also disclose any risks related to Nasdaq delisting
due to the
       significant dilution of these issuances, if applicable.
Background
Background Regarding a Financing, page 31

4.     We note your disclosure that you are actively seeking additional capital
and that the
       Subsequent Financing could result in the issuance of 700,000,000 to
1,200,000,000
       shares of common stock. We also note your disclosure that the Warrants
will not be
       exercisable unless and until, among other things, you consummate a
Financing. Please
       tell whether you have entered into any agreements for a financing, and
the status of
       any negotiations for a financing, if material. Revise your disclosure
accordingly.
Potential Effects of the Increased Authorized Share Amendment, page 32

5.     We note your disclosure that, if the Increased Authorized Share
Amendment and the
       Nasdaq Listing Approvals are approved and you issue shares of Common
Stock upon
       exercise of the Warrants and in connection with a Financing, the
ownership of your
       Common Stock will be concentrated in a limited number of holders. To the
extent
       known and estimable, please disclose the potential beneficial ownership
concentration
       and identify the relevant holders. For example, we note your disclosure
on page 47
       discussing the beneficial ownership and potential beneficial ownership
of Khosla
       Ventures and its affiliates.
 June 6, 2025
Page 3

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Please contact Jane Park at 202-551-7439 or Katherine Bagley at
202-551-2545 with
any questions.

                                                         Sincerely,

                                                         Division of
Corporation Finance
                                                         Office of Industrial
Applications and
                                                         Services
cc:   Marisa Stavenas, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._